glycylglutamine has been researched along with Drug Withdrawal Symptoms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavun, S; Göktalay, G; Millington, WR | 1 |
| Cavun, S; Göktalay, G; Hamilton, JR; Levendusky, MC; Millington, WR | 1 |
2 other study(ies) available for glycylglutamine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; beta-Endorphin; Conditioning, Operant; Dipeptides; Dose-Response Relationship, Drug; Drug Tolerance; Food; Injections, Intraventricular; Male; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Substance Withdrawal Syndrome | 2005 |
Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Avoidance Learning; Conditioning, Psychological; Dipeptides; Dose-Response Relationship, Drug; Injections, Intraventricular; Injections, Subcutaneous; Male; Mecamylamine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Peptides, Cyclic; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Time Factors | 2006 |